Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder
Phase 2
Completed
- Conditions
- Major Depressive DisorderAntidepressant Treatment Response
- Interventions
- Registration Number
- NCT00931775
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Brief Summary
The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.
- Detailed Description
Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram + placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected from a general hospital.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Patients with a depressive episode
- HDRS score > 18
- Written informed consent
Read More
Exclusion Criteria
- suicidal risk > 3
- severe organic illness
- other psychotropic drugs
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Citalopram + placebo Pindolol Citalopram 20 mg/day t.i.d Citalopram + pindolol Pindolol Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
- Primary Outcome Measures
Name Time Method Scores on Hamilton Depression Rating Scale 8 time points through 6 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Outpatients Service of Psychiatry Department. Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Catalonia, Spain